Cargando…

The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy

BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wenbin, Ding, Qiang, Liang, Xiuqing, He, Zhongyuan, Zha, Xiaoming, Liu, Xiaoan, Wang, Shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353923/
https://www.ncbi.nlm.nih.gov/pubmed/22615953
http://dx.doi.org/10.1371/journal.pone.0037249
_version_ 1782233119203524608
author Zhou, Wenbin
Ding, Qiang
Liang, Xiuqing
He, Zhongyuan
Zha, Xiaoming
Liu, Xiaoan
Wang, Shui
author_facet Zhou, Wenbin
Ding, Qiang
Liang, Xiuqing
He, Zhongyuan
Zha, Xiaoming
Liu, Xiaoan
Wang, Shui
author_sort Zhou, Wenbin
collection PubMed
description BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed. METHODOLOGY AND PRINCIPAL FINDINGS: Between October 2008 and March 2010, 186 consecutive premenopausal patients, treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34–40.88, P<0.001) and previous childbearing (OR: 3.17, 95% CI: 1.06–9.47, P = 0.038) were significantly associated with probability of CIA. Compared to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate of CIA (P>0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group (34.62%) (P = 0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P = 0.037). CONCLUSIONS: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-induced infertility.
format Online
Article
Text
id pubmed-3353923
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33539232012-05-21 The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy Zhou, Wenbin Ding, Qiang Liang, Xiuqing He, Zhongyuan Zha, Xiaoming Liu, Xiaoan Wang, Shui PLoS One Research Article BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed. METHODOLOGY AND PRINCIPAL FINDINGS: Between October 2008 and March 2010, 186 consecutive premenopausal patients, treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34–40.88, P<0.001) and previous childbearing (OR: 3.17, 95% CI: 1.06–9.47, P = 0.038) were significantly associated with probability of CIA. Compared to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate of CIA (P>0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group (34.62%) (P = 0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P = 0.037). CONCLUSIONS: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-induced infertility. Public Library of Science 2012-05-16 /pmc/articles/PMC3353923/ /pubmed/22615953 http://dx.doi.org/10.1371/journal.pone.0037249 Text en Zhou et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhou, Wenbin
Ding, Qiang
Liang, Xiuqing
He, Zhongyuan
Zha, Xiaoming
Liu, Xiaoan
Wang, Shui
The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title_full The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title_fullStr The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title_full_unstemmed The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title_short The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
title_sort risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353923/
https://www.ncbi.nlm.nih.gov/pubmed/22615953
http://dx.doi.org/10.1371/journal.pone.0037249
work_keys_str_mv AT zhouwenbin theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT dingqiang theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT liangxiuqing theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT hezhongyuan theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT zhaxiaoming theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT liuxiaoan theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT wangshui theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT zhouwenbin riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT dingqiang riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT liangxiuqing riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT hezhongyuan riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT zhaxiaoming riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT liuxiaoan riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy
AT wangshui riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy